BioAtla (BCAB) and Context Therapeutics (CNTX) said Monday they have entered into an agreement granting Context an exclusive worldwide license to develop, produce and market BA3362, BioAtla's Nectin-4 x CD3 T-cell engager.
Under the terms, BioAtla will receive $15 million in upfront and near-term milestones, and is eligible to receive up to $133.5 million in total payments along with tiered royalties on net sales, the companies said.
Context will assume and fund all development and commercialization activities, the companies said.
Price: 1.70, Change: -0.02, Percent Change: -1.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments